



Daewon Pharmaceutical's believe that customers is the most important core value of corporate management. Since Established in 1958 based on the founding philosophy of "partner for people to promise their healthy lives", we have effort to protect the healthy life of people as a company specialized in pure competent pharmaceutical company.

Daewon Pharm is a pharmaceutical company that based on its advanced facility & Plant, investment and excellent R&D capabilities, we have developed the ' Pelubi Tab', a new drug for the Korean & Global market.

Main Products

Category	Product	Molecule
Analgesic	Pelubi CR Tab.®	Pelubiprofen
	Pelubi Tab.®	Pelubiprofen
	Nerexone SR Tab.	Eperisone
Cardiovascular	Clow Tab.	Rosuvastatin
	Lipiwon Tab.	Atorvastatin
	Exombi Tab.	Varsartan/amlodipine
	TG Fenone Tab.	Choline Fenofibrate
	Twincombi Tab.	Telmisartan/amlodipine
	Tri-in-one Tab.	Telmisartan/amlodipine/Rosuvastatin
	Uptava Cap.	Pitavastatin/Fenofibrate
	Eswonamp Tab.	Esomeprazole
Gastrointestinal	Otillen F Tab.	Artemisia herb isopropanol soft extract(20→1)
	Codaewon Forte Syr.	Dihydrocodeine/ammonium chloride /chlorpheniramine/dl-methylephedrine
Respiratory	Beposta SR Tab.	Bepotastine
	Beposta SR Tab.	Bepotastine
	Elsteine Tab.	Erdosteine
Analgesic	Wontran ER Tab.	Acetaminophen/Tramadol
	Lycaneuro ER Tab.	Pregabalin
	Freefol MCT Inj.1,2%	Propofol
Others	Renamezin Cap.	Spherical adsorptive carbon

R&D Pipeline

Category	Project Code	Indication	Stage
New chemical entity	DW-4301	Cardiovascular Disease	Phase I
	DW-4902	uterine disease	Phase I
Generic	DW-2801	Gastrointestinal disease	Phase I
	DW-5903	Cardiovascular Disease	Pre-Clinical
Incrementally modified drug	DW-1601	Respiratory Disease	Phase III
	DW-1807	Respiratory Disease	Phase I
	DW-1806	Metabolic Disorders	Phase I
	DW-1805	Metabolic Disorders	Pre-Clinical
	DW-8809	Gastrointestinal disease	Pre-Clinical
	DW-1804	Metabolic Disorders	NDA submit
	DW-1808	degenerative disease	Pre-Clinical
	DW-1809	degenerative disease	Phase I

CEO

Seung Ryel Baek

Location

386 cheonhodaero-ro, Seongdong-gu, Seoul #04808, Korea

Specialty

1. IMD (incrementally modified drug)
2. NCE (New chemical entity)
3. First Generic

Tel / Fax / E-mail

T. 82-2-2204-7000

F. 82-2-3436-4878